p-values Search Results


genome wide association data ( p-values)  (Broad Institute Inc)
90
Broad Institute Inc genome wide association data ( p-values)
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Genome Wide Association Data ( P Values), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genome wide association data ( p-values)/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
genome wide association data ( p-values) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
student’s t-test analysis with p values of 50.005  (GraphPad Software Inc)
90
GraphPad Software Inc student’s t-test analysis with p values of 50.005
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Student’s T Test Analysis With P Values Of 50.005, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/student’s t-test analysis with p values of 50.005/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
student’s t-test analysis with p values of 50.005 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
snp association p-values  (23andMe)
90
23andMe snp association p-values
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Snp Association P Values, supplied by 23andMe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/snp association p-values/product/23andMe
Average 90 stars, based on 1 article reviews
snp association p-values - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
p-values  (Amstat Industries)
90
Amstat Industries p-values
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
P Values, supplied by Amstat Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-values/product/Amstat Industries
Average 90 stars, based on 1 article reviews
p-values - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
p-values from anova  (SAS institute)
90
SAS institute p-values from anova
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
P Values From Anova, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-values from anova/product/SAS institute
Average 90 stars, based on 1 article reviews
p-values from anova - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
bonferroni-adjusted  (SPSS Inc)
90
SPSS Inc bonferroni-adjusted
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Bonferroni Adjusted, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bonferroni-adjusted/product/SPSS Inc
Average 90 stars, based on 1 article reviews
bonferroni-adjusted - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
elisa s / p values  (IDEXX)
90
IDEXX elisa s / p values
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Elisa S / P Values, supplied by IDEXX, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa s / p values/product/IDEXX
Average 90 stars, based on 1 article reviews
elisa s / p values - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
spearman correlation coefficients and twotailed p values  (GraphPad Software Inc)
90
GraphPad Software Inc spearman correlation coefficients and twotailed p values
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Spearman Correlation Coefficients And Twotailed P Values, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spearman correlation coefficients and twotailed p values/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
spearman correlation coefficients and twotailed p values - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
adjusted t-test with p values corrected by the bonferroni method  (GraphPad Software Inc)
90
GraphPad Software Inc adjusted t-test with p values corrected by the bonferroni method
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Adjusted T Test With P Values Corrected By The Bonferroni Method, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adjusted t-test with p values corrected by the bonferroni method/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
adjusted t-test with p values corrected by the bonferroni method - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
p-value signal tracks  (Epigenomics ag)
90
Epigenomics ag p-value signal tracks
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
P Value Signal Tracks, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-value signal tracks/product/Epigenomics ag
Average 90 stars, based on 1 article reviews
p-value signal tracks - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
p values <0.05  (SAS institute)
90
SAS institute p values <0.05
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
P Values <0.05, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p values <0.05/product/SAS institute
Average 90 stars, based on 1 article reviews
p values <0.05 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
pearson correlation efficient (r) and p values of gene pairs  (RStudio)
90
RStudio pearson correlation efficient (r) and p values of gene pairs
We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
Pearson Correlation Efficient (R) And P Values Of Gene Pairs, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pearson correlation efficient (r) and p values of gene pairs/product/RStudio
Average 90 stars, based on 1 article reviews
pearson correlation efficient (r) and p values of gene pairs - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.

Journal: PLoS Genetics

Article Title: Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum

doi: 10.1371/journal.pgen.1000282

Figure Lengend Snippet: We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.

Article Snippet: Genome wide association data ( p -values) from three recent GWA studies was downloaded on 21 February 2008 from http://www.broad.mit.edu/diabetes/scandinavs/metatraits.html (Broad Institute ) and http://www.sph.umich.edu/csg/abecasis/public/lipids/ (University of Michigan ) and on 14 March 2008 from http://www.wtccc.org.uk/info/summary_stats.shtml (Wellcome Trust Case Control Consortium ).

Techniques: Functional Assay, Genome Wide, Activity Assay